LLY250103C800000
- 0.05
- 0.000.00%
Eli Lilly and Co Newsroom
Argus Research Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,020
Eli Lilly & Co: Buy Rating Backed by Promising Orfoglipron Trials and Strong Pharmaceutical Pipeline
Evercore Maintains Eli Lilly and Co(LLY.US) With Hold Rating
DBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,115
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Guggenheim Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $973
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $950
TD Cowen Adjusts Price Target on Eli Lilly to $900 From $1,050, Maintains Buy Rating
Berenberg Bank Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $970
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $996
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $996
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $997 to $1,250
Eli Lilly & Co: Strong Growth Prospects and Strategic Investments Justify Buy Rating
Jefferies Adjusts Price Target on Eli Lilly to $996 From $994
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,029
Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,146
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994